Plenary & Invited Speakers

Disclaimers:

a) The information on this website is regularly updated to reflect the latest developments. While we strive for accuracy, details (including schedules, speakers, and topics) may change without prior notice.

b) We are thrilled to announce that additional Plenary and Invited Speakers are being added to the conference program. Updates will be posted frequently, so please check back for the most current information.


Prof. Dr Chas Bountra
Translational Medicine
University of Oxford,
England

[ View Profile ]

Prof. Dr Christopher Twelves

Medical Oncology
Leeds University,
United Kingdom

[ View Profile ]

Prof. Dr Karolien De Bosscher

Nuclear Receptor Signalling
Ghent University,
Belgium

[ View Profile ]

Prof. Dr K. Miraz Rahman

Drug Design & Synthesis
King’s College London,
United Kingdom

[ View Profile ]

Prof. Dr Roger Ho Chun Man

Psychiatry
National University of Singapore,
Singapore

[ View Profile ]

Prof. Dr Paul Chi-Lui Ho

Pharmaceutical Science
Monash University,
Malaysia

[ View Profile ]

Prof. Dr Hasniza Zaman Huri

Precision Medicine
Universiti Malaya,
Malaysia

[ View Profile ]

Prof. Dr Zamberi Sekawi

Medical Microbiology
Universiti Putra Malaysia,
Malaysia

[ View Profile ]

Prof. Dr Amedeo Amedei

Immunology
University of Florence,
Italy

[ View Profile ]

Prof. Dr Mohd Cairul Iqbal Mohd Amin

Pharmaceutics
Universiti Kebangsaan Malaysia,
Malaysia

[ View Profile ]

Prof. Dr Claire Wells

Cancer Cell Biology
King’s College London,
United Kingdom

[ View Profile ]

Prof. Dr Lim Lee-Ling

Diabetes Care
Universiti Malaya,
Malaysia

[ View Profile ]

Prof. Dr Lim Shen-Yang

Neurology
Universiti Malaya,
Malaysia

[ View Profile ]

Dr Muthukkumaran Thiagarajan

Clinical Oncology
Hospital Kuala Lumpur,
Malaysia

[ View Profile ]

Dr Lin Kooi Ong

Translational Neurorecovery
University of Southern Queensland,
Australia

[ View Profile ]

Dr Vijay Ivaturi

Pharmacometrics
Pumas-AI Inc,
USA

[ View Profile ]

 


Prof. Dr Chas Bountra
Translational Medicine
University of Oxford, England

----------------------------------------------------------------------

Prof. Dr Chas Bountra

Chas is Professor of Translational Medicine (Nuffield Department of Clinical Medicine) and Professorial Fellow (Keble College) at the University of Oxford. He has worked with senior colleagues to attract funding and establish a ‘Target Discovery Institute’, a ‘Dementia Drug Discovery Institute’ the ‘Centre for Medicines Discovery’ and an incubator (‘BioEscalator’) within the University, and a national facility (Rosalind Franklin Institute’) developing new drug enabling technologies.

As Pro-Vice Chancellor for Innovation - University of Oxford (2018-2025) he has incentivised academics to create new companies, increased the number of female founders and females on C suite, created a university wide entrepreneurship training programme, built connectivity with > 300 university spinouts, science parks and large local science infrastructures, catalysed industry partnerships and enabled increased venture capital and philanthropic income. By championing role models across the university, he has changed the attitude to innovation across the university. As Director of Oxford University Innovation, he has helped build arguably the best university technology transfer office, in the country. Colleagues have now suggested that Oxfordshire is the fastest growing innovation ecosystem in the world.  More recently he has been attracting more investors, corporates and developers into the ecosystem. His goal is to build the first trillion pound company in the UK.

As Director of the Structural Genomics Consortium (2008-2020) he established a leading research group in human protein structural biology and epigenetics chemical biology, and arguably one of the most successful open innovation, public-private partnerships in the world. The group generated several thousand drug discovery tools, enabled several thousand publications, proprietary programmes, and the creation of new companies. The team accelerated innovation in drug target discovery.

As Vice President and Head of Biology at GlaxoSmithKline (2002-2008), he was involved in the identification of >30 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases. In earlier roles in Glaxo or GlaxoWellcome, he was involved in the launch and development of the first treatment for Irritable Bowel Syndrome (Alosetron) and was the first to show that neurokinin NK1 antagonists are anti-emetic in preclinical and clinical studies.

In all these roles he has mentored and help grow the careers of many young researchers.

He has through Board roles advised many funders, charities, universities, research institutes, SMEs and pharma companies, and helped >40 teams of innovators and entrepreneurs create new commercial and social enterprises. His current passions are developing new treatments for dementia and multi-morbidities associated with ageing, driving new approaches to improve the lives of patients living with psychiatric disease, and accelerating innovations to mitigate the climate emergency.

Note: Click [x] on top-right or anywhere on this pop-up to exit

 

 


Prof. Dr Christopher Twelves
Medical Oncology
Leeds University, United Kingdom

----------------------------------------------------------------------

Professor Dr. Christopher Twelves is Professor of Clinical Cancer Pharmacology and Oncology and Director of the NIHR Leeds Clinical Research Facility.

He is a medical oncologist with a particular interest in new drug development and clinical pharmacology; his clinical practice has been in colorectal and breast cancer.

After training as an oncologist in London he was Senior Lecturer, then Reader, in Medical Oncology in Glasgow at the Beatson Oncology Centre before taking up his current post at the University of Leeds and St James’s Institute of Oncology.

Professor Twelves has been a member of the Cancer Research UK New Agents Committee, Chair of the New Drug Development Group of the EORTC and was Scientific Chair of the Berlin 2009 ECCO-ESMO 34 meeting.  He has been involved in the development of several important new agents including capecitabine, and eribulin.  Professor Twelves has a particular interest in early clinical trials and pharmacokinetics including intra-tumoural drug pharmacokinetics.

Professor Twelves has published almost 300 papers in journals including the New England Journal of Medicine, Lancet, Journal of Clinical Oncology and BMJ as well as spoking at numerous international meetings.  He has also edited, or contributed to, several books including one on Phase I clinical trials and another on the design of Phase II clinical trials.

Note: Click [x] on top-right or anywhere on this pop-up to exit

 

 


Prof. Dr Karolien De Bosscher
Nuclear Receptor Signalling
Ghent University, Belgium

----------------------------------------------------------------------

Professor Dr Karolien De Bosscher, a molecular biologist, earned her Ph.D. from UGent in 2000. Following postdoctoral research at Cancer Research UK with an EMBO fellowship she returned to Belgium to conduct nuclear receptor research as a postdoctoral fellow of FWO-Vlaanderen. In 2013, she secured a research professorship, combining research and teaching at UGent. From 2019 onwards, she is a full professor at UGent and principal investigator at the VIB Center for Medical Biotechnology.

Throughout her career, Dr. De Bosscher focused on unraveling nuclear receptor intricacies, exploring anti-inflammatory and anti-cancer mechanisms. Her team investigates selective glucocorticoid receptor modulation, metabolic actions of nuclear receptors, and crosstalk mechanisms in hematological cancers. Dr. De Bosscher's lab decodes how nuclear receptors transduce signals, aiming to innovate receptor-targeting strategies for enhanced therapeutic benefits. The team develops cell-based tools to capture nuclear receptors' complexity, contributing to drug discovery platforms.

Note: Click [x] on top-right or anywhere on this pop-up to exit

 

 


Professor Dr K. Miraz Rahman
Drug Design & Synthesis
King's College London, United Kingdom

----------------------------------------------------------------------

Professor Dr K. Miraz Rahman is a Professor of Medicinal Chemistry at King’s College London, with extensive expertise in both early- and late-stage drug discovery. He graduated as a pharmacist from the Faculty of Pharmacy at the University of Dhaka, Bangladesh, in 1996. After three years in the industry, he transitioned to academia, completed his PhD in synthetic medicinal chemistry at the London School of Pharmacy (now UCL School of Pharmacy), and worked as a CRUK Research Fellow for three years. In 2012, he joined King’s College London as a Lecturer and was subsequently promoted to Chair in Medicinal Chemistry in 2021.

He currently serves as Head of the Drug Discovery Research Division at King’s College London. Additionally, he is the Antimicrobial Research Theme Lead and Director of the MRC DTP iCASE Programme, one of the largest UKRI-funded industrial PhD programmes in the UK.  His research focuses on the application of advanced computational chemistry, synthetic medicinal chemistry, and chemical biology techniques to design, synthesize, and evaluate novel drug-like chemical scaffolds as anticancer and antimicrobial agents.

Miraz is committed to translating innovative laboratory research into commercialization and patient care. He holds 20 patents as an inventor and has co-founded several university spin-out companies, including Pheon Therapeutics, a clinical-stage company developing first-in-class antibody-drug conjugates for the treatment of solid tumours.

Note: Click [x] on top-right or anywhere outside this pop-up to exit

 

 


Prof. Dr Roger Ho Chun Man
Psychiatry
National University of Singapore, Singapore

----------------------------------------------------------------------

Professor Roger Ho is a Professor and Senior Consultant Psychiatrist at the National University of Singapore (NUS) and National University Hospital. He is a Visiting Professor at the Hong Kong University of Science and Technology (HKUST) to prepare for the third medical school in Hong Kong. He obtained MBBS and MD from the University of Hong Kong. His research interest is the clinical application of functional near-infrared spectroscopy (fNIRS) and artificial intelligence in Psychiatry. He is a Fellow of the Royal College of Psychiatrists and Royal College of Physicians (Canada and Edinburgh). He has published over 650 papers, mainly on mood disorders and several academic books. From 2021 to 2024, he was named “Highly Cited Researcher” by Clarivate Analytics.

Note: Click [x] on top-right or anywhere outside this pop-up to exit

 


Prof. Paul Chi-Lui Ho
Pharmaceutical Science
Monash University, Malaysia

----------------------------------------------------------------------

Professor Paul C. Ho, a pharmaceutical scientist, earned his B. Pharm. (Hons) and Ph.D. from the University of Queensland and completed post-doctoral fellowships at the University of Michigan and the Queensland Institute of Medical Research.

Currently, he holds prestigious positions as Professor of Pharmacy at Monash University Malaysia, Emeritus Professor at the National University of Singapore (NUS), and Honorary Professor at Xi'an Jiaotong University. With over 200 publications in top-tier journals like Biomaterials, Small, Nature Medicine, Asian Journal of Pharmaceutical Sciences, and JACS, and an H-index of 55, Professor Ho has made significant contributions to pharmacokinetics, exploring how disease states and organ functions influence drug behavior. His research has expanded into biomarkers and omics studies, leveraging advanced technologies to improve personalized medicine. Recognized for his expertise, he received the AAPS Outstanding Medical Graduate Drug Technology Mentor Award and the NUS Distinguished Scientist Award in 2011.

Beyond academia, he serves as a consultant to pharmaceutical companies, reviews research proposals for international agencies, and contributes to additive manufacturing, particularly in 3D printing for pharmaceuticals, as a thrust lead at AM@NUS. His multidisciplinary work continues to shape drug development and therapeutic innovation.

Note: Click [x] on top-right or anywhere outside this pop-up to exit

 


Prof. Dr Hasniza Zaman Huri
Precision Medicine
Universiti Malaya, Malaysia

----------------------------------------------------------------------

Professor Dr. Hasniza Zaman Huri is a distinguished academic pharmacist and the founding Dean of the Faculty of Pharmacy at Universiti Malaya. She is currently serving as the Deputy Vice Chancellor of Academic and International at Universiti Malaya. Under her leadership, the faculty achieved numerous milestones, including becoming a founding member of the Global Alliance for the Development of Pharmaceutical Science (GADPS) and ranking #72 for Pharmacy in the QS World University Rankings 2024.

Dr. Hasniza's expertise in clinical pharmacy, precision medicine, and targeted therapy has earned her global recognition, including the World Class Professor Programme by the Indonesian Government in 2022. Her research focuses on targeted therapy, drug utilization, and precision medicine, particularly in metabolic diseases. She has published over 100 papers in Web of Science and served as a keynote speaker at international conferences.

Dr. Hasniza's leadership in clinical trials, particularly at the University Malaya Medical Centre's Clinical Investigation Centre (CIC), has gained the centre international distinction, including being a top clinical trial service provider in Asia. She received the MPS Outstanding Leadership Award in 2024 and the Best Academic Administrator award in 2015. Dr. Hasniza is also an Honorary Visiting Consultant at CIC and a member of Malaysia's Drug Control Authority.

Note: Click [x] on top-right or anywhere on this pop-up to exit

 


Prof. Dr Zamberi Sekawi
Medical Microbiology
Universiti Putra Malaysia, Malaysia

----------------------------------------------------------------------

Prof. Dr Zamberi Sekawi holds a professorship and serves as a senior consultant clinical microbiologist at Universiti Putra Malaysia. He has also taken on leadership roles within the university, including as Deputy Vice Chancellor for Research and Innovation and former Dean of the Faculty of Medicine and Health Sciences.

Professor Sekawi’s experience extends internationally, having served as a Technical Officer for the World Health Organization in Fiji and as a Visiting Scientist at the Burnet Institute in Australia. He has contributed to the medical community through roles in organizations such as the Malaysian Society of Infectious Diseases and Chemotherapy, the Asia Pacific Society of Clinical Microbiology and Infection, and the International Society for Infectious Diseases.

As a vaccine advocate, Professor Sekawi actively promotes the importance of immunization in preventing infectious diseases and improving public health outcomes. His research focuses on infectious diseases, including influenza, antimicrobial resistance, and leptospirosis. His leadership in a major grant initiative on leptospirosis in Malaysia resulted in the formation of the Malaysian Leptospirosis Research Group, which continues to make a positive impact in the field. He had published more than 180 journal articles and with a Scopus h-index of 29.

Note: Click [x] on top-right or anywhere on this pop-up to exit

 


Prof. Dr Amedeo Amedei
Immunology
University of Florence, Italy

----------------------------------------------------------------------

Prof. Dr Amedeo Amedei graduated with full marks and honours in Biology at Florence University in 1996. He started his scientific career studying the role of Th1/Th2 lymphocytes in GVHD, atopic dermatitis and kidney rejection. After he examined the role of Helicobacter pylori-specific immune response in gastric diseases. In 2003 began his doctor’s degree in "Clinical and Sperimental Medicine". In 2005 he became researcher at Department of Experimental and Clinical Medicine (University of Florence), where in 2015 he was appointed Associate Professor. Actually, he is Full Professor of Immunology (from 2023). The Prof. Amedei has focused his scientific interests on the cancer immunology and the role of microbiota-immunity axis in inflammatory-correlated diseases (mainly Autoimmunity, Cancer, Neurodegenerative Disorders). More recently he started a new research topic: micro/nanoplastics and human health.

 The great quality of his international profile is documented by scientific production: 297 peer reviewed articles (h-index: 58 and 13,185 Citations), 12 book chapters and one patent ( https://www.scopus.com/authid/detail.uri?authorId=6603007335 ). The Prof. Amedei is serving as an editorial board member of 13 international journals, as Referee of 43 Journals, as Co-Editor-Chief of one Journal.  Finally,he carries out activities as scientific reviewer for international research projects of private and public entities. From 2016, he is in the Scientific Council of “Toscana Life Sciences” (TLS). To date he received more than of 10 million of euro by different proposals funded by several funding agencies, including Europe Commission, Italian Minister of Health, Tuscany Region, Nasa and local and international Foundations.

Note: Click [x] on top-right or anywhere on this pop-up to exit

 


Prof. Dr Mohd Cairul Iqbal Mohd Amin
Pharmaceutics
Universiti Kebangsaan Malaysia, Malaysia

----------------------------------------------------------------------

Prof. Mohd Cairul Iqbal Mohd Amin is a prominent figure in the field of Pharmaceutics at Universiti Kebangsaan Malaysia (UKM), where he has served since 1997.

He held key leadership positions including Deputy Director General at the Department of Higher Education (2019–2021), and Deputy Dean roles for Postgraduate, Research & Innovation, and Undergraduate, Alumni & International Affairs. He played a pivotal role in UKM's Grand Challenges initiative, driving research under the Malaysia and Wellness theme. An alumnus of the University of Manchester, UK, he holds a Ph.D. and Bachelor of Pharmacy. He has served as Visiting Professor or Scholar in Thailand, Indonesia, and India.

His research focuses on advanced drug delivery systems including hydrogels, bacterial cellulose-based carriers and nano delivery systems. He is currently leading studies on aerosolized immunoliposomes loaded with antiviral drugs to target SARS-CoV-2. With over 100 high-impact publications and the supervision of 35 postgraduate students, he has secured nearly RM 12 million in national and international grants. He also contributes to educational quality assurance through his roles with the Pharmacy Board of Malaysia and MQA. Notably, he founded and presided over the Malaysian Local Chapter of the Controlled Release Society (MyCRS), advocating controlled release technologies across multiple industries.

Note: Click [x] on top-right or anywhere on this pop-up to exit

 

 


Prof. Dr Claire Wells
Cancer Cell Biology
King's College London, United Kingdom

----------------------------------------------------------------------

Prof. Claire Wells is a Professor of Cancer Cell Biology at King's College London. She graduated with a 1st Class hons degree in Biology from University College London in 1993 and completed her PhD at King's College London in 1998.

Prof. Wells has a broad interest in cell migration studies and has focused her research on understanding the molecular signaling pathways regulated by p-21 activated kinases (PAKs) during cancer cell metastasis. Her work uses protein biochemistry coupled with advanced microscopy and in vivo model systems to explore the signaling landscape of PAKs during cancer cell migration and invasion. She specializes in the study of solid tumors with a focus on pancreatic, breast and prostate cancer. Her research team and collaborative partners have published 50 papers in this area.

She has also worked with Cancer Research UK for the last 10 years developing PAK specific inhibitors for clinical use. Claire is active in the British Society for Cell biology and the Royal Microscopical Society (RMS) where she was section Chair from 2016-2019 and now sits on RMS Council. She is on the editorial board of the European Journal of Cell Biology and is currently a member of the French National Institute Cancer Research, Against Breast Cancer and Barts Cancer Charity funding committees. Prof. Wells is Editor in Chief of the journal Cell Adhesion and Migration. 

Note: Click [x] on top-right or anywhere on this pop-up to exit

 

Prof. Dr Lim Lee-Ling
Diabetes Care
Universiti Malaya, Malaysia

----------------------------------------------------------------------

MBBS (Mal), PhD (CUHK), FRCP (Lond), FRCP (Edin), FRCP (Glasgow), AM

Prof. Dr Lim Lee-Ling is a Consultant Endocrinologist and Head of the Diabetes Care Unit at the Universiti Malaya, Kuala Lumpur, Malaysia. She also holds honorary positions at the Chinese University of Hong Kong and the Baker Heart and Diabetes Institute, Melbourne, Australia. As a clinician-scientist, Dr. Lim’s major areas of interest are cardiometabolic medicine (epidemiology, molecular, and implementation science). 

Dr Lim is the Co-Chair of The Lancet Commission on Global Implementation of Precision Medicine. She also sits on the Scientific Work Groups of the American Diabetes Association / European Association for the Study of Diabetes (ADA/EASD) Precision Medicine in Diabetes Initiative and the World Health Organization (WHO) Global Diabetes Compact. She has published more than 120 peer-reviewed articles, including The Lancet, Nature, Diabetes Care, and Science Bulletin, with an H-index of 46.

Dr. Lim has received several awards, including the Universiti Malaya’s Top Cited Researcher 2024, World’s Top 2% Scientists by Stanford University (2022-2024), and the EFSD Albert Renold Fellowship, tenable at the University of Oxford, UK. She is an Editorial Board Member of several Tier 1 Web of Science-indexed journals. She is also the Honorary Assistant Secretary of the Malaysian Endocrine and Metabolic Society (MEMS) 2022-2024, and Council Member of Diabetes Malaysia, a country affiliate of the International Diabetes Federation.

Note: Click [x] on top-right or anywhere on this pop-up to exit

 


Prof. Dr Lim Shen-Yang
Neurology
Universiti Malaya, Malaysia

----------------------------------------------------------------------

Professor Lim is a Movement Disorders neurologist at the University of Malaya, Kuala Lumpur, Malaysia.

Dr. Lim is an expert on Parkinson’s and related conditions and has published extensively in these areas.

He is currently Chair of the International Parkinson’s & Movement Disorder Society (MDS), Asian-Oceanian Section, and a past-Chair (and founding member) of the Movement Disorders Council Malaysia (MDC).

Weblink: https://umexpert.um.edu.my/limshenyang.html

Note: Click [x] on top-right or anywhere on this pop-up to exit

 


Dr Muthukkumaran Thiagarajan
Clinical Oncology
Hospital Kuala Lumpur, Malaysia

----------------------------------------------------------------------

Dr Muthukkumaran obtained his Masters in Clinical Oncology from University of Malaya in 2013. He previously served at Sabah Women and Children Hospital and currently based at Hospital Kuala Lumpur’s Department of Radiotherapy and Oncology. 

Dr Muthukkumaran has a special interest in pulmonary oncology, genitourinary oncology, neuro oncology (including stereotactic cranial radiosurgery) and paediatric radiation. He is actively involved in both industry-sponsored and investigator-initiated clinical research. 

Dr Muthukkumaran is currently the President of Malaysian Oncological Society (MOS). He is a national representative to the Federation of Asian Organizations for Radiation Oncology (FARO) and International Atomic Energy Agency (IAEA). 

Note: Click [x] on top-right or anywhere on this pop-up to exit

 


Dr Lin Kooi Ong
Translational Neurorecovery
University of Southern Queensland, Australia

----------------------------------------------------------------------

Dr Lin Kooi Ong B Biomed Med Sci (Hons), PhD is a Senior Lecturer in Biomedical Sciences at University of Southern Queensland. Dr Ong is a multifaceted mid-career academic with significant teaching and administrative responsibilities while leading a research group. He is the Medical Sciences Discipline Lead with 14 direct reports, Program Director of Biomedical Sciences and teaches over 800 students per year across Medical Sciences, Medicine, Paramedicine and Nursing Programs. He heads the Translational Neurorecovery and Stress Biomarkers laboratory, focusing on understanding the pathophysiology of post-stroke secondary neurodegeneration and cognitive impairment, stress biomarkers as well as development of therapeutic targets for brain recovery.

Dr Ong's research career is on an upward trajectory having published 57 peer-review articles and 2 book chapters, as well as over 25 invitations to present his work at conferences, institutions, research workshops/schools and community presentations. He has published pioneering research on post-stroke secondary neurodegeneration and cognitive deficit in pre-eminent journals including Brain, Stroke and Journal of Cerebral Blood Flow & Metabolism. He has successfully graduated 4 PhDs and 18 undergraduates, and is currently supervising 2 PhDs, 1 Master and 1 undergraduate.

He serves as research mentor for clinicians and health service staff to improve research capability within Darling Downs Health. Dr Ong was appointed several leadership and professional roles including Emerging Leaders Group of International Stroke Recovery and Rehabilitation Alliance, Young Scientists Network – Academy of Sciences Malaysia, Editorial Board Fellows of Neuroscience and Grant Peer Reviewer for NHMRC and Heart Foundation.

Note: Click [x] on top-right or anywhere on this pop-up to exit

 


Dr Vijay Ivaturi
Pharmacometrics
Pumas-AI Inc, USA

----------------------------------------------------------------------

Dr Vijay Ivaturi holds the positions of Co-Founder and CEO at PumasAI, as well as the Endowed Chair and Professor at the Centre for Pharmacometrics at Manipal University, India. Before assuming his current roles, he was a member of the faculty at the University of Maryland Baltimore School of Pharmacy’s Center for Translational Medicine for a decade, subsequently transitioning to an Adjunct Faculty position.

With a steadfast commitment to the advancement of pharmacometrics, Vijay has been an active participant in the pharmacometrics community since the founding of the American Conference on Pharmacometrics (ACoP) in 2008. He has undertaken various responsibilities within the International Society of Pharmacometrics (ISoP) since 2014 and played a pivotal role as the Chair of the Education Committee for several years before being appointed to the ISoP Board in 2020. He is currently the President of ISoP for a 2-year term starting January 2024.

Trained as a clinical pharmacologist and pharmacometrician, Vijay has been instrumental in leading Project Pumas from its inception, passionately developing it into a revolutionary modeling and simulation platform since 2017. His research primarily focuses on the creation of innovative tools and methodologies to enhance drug development and clinical therapeutics.

Vijay completed his doctoral studies in Experimental and Clinical Pharmacology at the University of Minnesota, followed by a post-doctoral fellowship in Pharmacometrics at Uppsala University, Sweden. At the University of Maryland Baltimore, his primary research interest was in developing tools and methods to bridge the gap between decision-makers and scientists, with a special focus on clinical therapeutics in pediatrics. With over 18 years of experience in drug development, he has also contributed to key policy-crafting projects as an ORISE research scholar at the US Food and Drug Administration (FDA).

Note: Click [x] on top-right or anywhere on this pop-up to exit